ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 541

An Essential Role For Caspase-1 In The Induction Of Murine Lupus and Its Associated Vascular Damage

J. Michelle Kahlenberg1, Srilakshmi Yalavarthi2, Wenpu Zhao2, Jeffrey Hodgin3, Tamra J. Reed4, Noriko M. Tsuji5 and Mariana J. Kaplan6, 1Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2University of Michigan Rheumatology, Ann Arbor, MI, 3Department of Pathology, University of Michigan, Ann Arbor, MI, 4Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, 53Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan, 6Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantibodies, inflammasome activation, interferons and nephritis, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune syndrome associated with organ damage and an elevated risk of cardiovascular disease (CVD) resulting from activation of both innate and adaptive immune pathways.  Recently, increased activation of the inflammasome machinery in SLE has been described. This study explores if caspase-1, the central enzyme of the inflammasome, plays a role in the development of SLE and its associated vascular dysfunction, using the pristane model of lupus. 

Methods: Eight-week old wild-type or caspase-1 -/- mice were exposed to PBS or pristane via intraperitoneal injection.  Six months post injection, mice were euthanized and the development of a lupus phenotype and vascular dysfunction was assessed. 

Results: Both wild-type and caspase-1 KO mice develop a vigorous inflammatory response to pristane; however, cell death following pristane exposure is decreased in caspase-1 -/- mice.  While wild-type mice exposed to pristane develop autoantibodies and a strong type I IFN response, mice lacking caspase-1 are significantly protected from these features, including pristane-induced vascular dysfunction.  Further, the development of immune-complex glomerulonephritis, prominent after pristane exposure in wild-type mice, is significantly abrogated in caspase-1 -/- mice. 

Conclusion: These results indicate that caspase-1 is an essential component in the development of lupus and its associated vascular dysfunction following exposure to pristane.  Importantly, caspase-1 may modulate autoantigen generation through regulation of cell death.  Thus, caspase-1 may play an important role in the cross-talk between environmental exposures and autoimmunity development, providing a novel pathway for therapeutic targeting.


Disclosure:

J. M. Kahlenberg,
None;

S. Yalavarthi,
None;

W. Zhao,
None;

J. Hodgin,
None;

T. J. Reed,
None;

N. M. Tsuji,
None;

M. J. Kaplan,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-essential-role-for-caspase-1-in-the-induction-of-murine-lupus-and-its-associated-vascular-damage/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology